Diagnos Inc. Advances AI‑Driven Retinal Analysis with CARA System Rollout
Diagnos Inc. (ADK.V) reported a modest 1.28 % uptick in its shares during the 24‑hour trading window that concluded at 10:28 PM Central Europe on Wednesday, 21 March 2026. The stock is currently trading around CAD 0.38 on major exchanges, reflecting a market capitalization of CAD 48.6 million and an outstanding supply of 124.5 million shares. In the most recent 24‑hour period, approximately CAD 97.9 k worth of Diagnos shares changed hands.
Since the close of last month, the stock has slipped 17.71 %. The simple moving average over the past 200 days sits at CAD 0.31, while the 52‑week high of CAD 0.53 was reached on 15 September 2026 and the 52‑week low of CAD 0.18 occurred on 25 May 2026.
CARA System Achieves Initial Deployment Milestone
Diagnos announced that its AI‑driven CARA System has completed its inaugural rollout across a network of optometry clinics throughout Canada, following Health Canada’s marketing authorization. The first phase of deployment has proven the system’s onboarding capacity and operational efficiency, with multiple sites installed rapidly and positive feedback from both clinicians and patients.
Users cited the system’s intuitive interface and the precision and speed of its retinal image analysis. The technology is positioned to accelerate diagnostic workflows and enhance patient outcomes, underpinned by an AI‑based platform that delivers faster and more accurate care.
In the coming months, Diagnos will focus on expanding the CARA System to clinics across all Canadian provinces, with the objective of embedding AI into routine ophthalmic practice nationwide.
Market Context and Peer Performance
In the last 24 hours, the following related stocks have exhibited the following movements:
| Stock | Ticker | 24‑hour Change | Current Price | Market Capitalisation |
|---|---|---|---|---|
| Bioharvest Sciences | BHST | –6.67 % | USD 1.67 | USD 40.8 million |
| Zincx | ZNX.V | 0 % | CAD 0.28 | CAD 56.9 million |
| Guideai Health | GDAI.NE | –9.09 % | CAD 1.00 | CAD 56.2 million |
| Grande Portage | GPG.V | –7.14 % | CAD 0.26 | CAD 56.2 million |
| Theralase | TLT.V | –2.63 % | CAD 0.19 | CAD 57.4 million |
These movements underscore the broader volatility within the health‑tech sector, yet Diagnos’s recent progress suggests a potential turnaround as the CARA System gains traction.
Company Overview
Diagnos Inc. is a Toronto‑based software solutions provider that specializes in developing and publishing a knowledge extraction platform for the intelligent analysis of digital retinal images. The platform is designed to enhance diagnostic capabilities in the healthcare industry worldwide by delivering accurate and reliable results. The company’s corporate website is www.diagnos.ca , and its shares trade on the TSX Venture Exchange under the symbol ADK.V.
